Last updated: February 20, 2026
What Is Darvon with Aspirin and Its Regulatory Status?
Darvon with aspirin combines propoxyphene, a now-discontinued opioid analgesic, with aspirin. It was marketed as a pain reliever. Originally approved in the United States in 1957, it gained popularity but was voluntarily withdrawn by the manufacturer in 2010 due to safety concerns related to propoxyphene. Regulatory actions significantly impact the drug's market viability.
How Did Regulatory Actions Influence Market Access?
The U.S. Food and Drug Administration (FDA) issued a final rule in November 2010 to withdraw Darvon and similar propoxyphene-containing products from the market, citing increased risk of cardiac toxicity and overdose. The decision directly affected prescribing patterns and sales volumes. Similar regulatory actions occurred globally, with Australia and Canada implementing bans or restrictions.
Impact Summary:
- Market withdrawal in the US: 2010
- International restrictions: 2010–2015
- Prescriber and consumer shift away from opioids with known safety risks
What Was the Sales and Revenue Trajectory Before Discontinuation?
Prior to removal from the market, Darvon with aspirin experienced declining sales, primarily due to safety concerns and competition from alternative analgesics such as NSAIDs and acetaminophen-based products.
| Year |
Estimated US Sales (USD million) |
Notes |
| 2008 |
120 |
Market peaked, high prescription rates |
| 2009 |
100 |
Rising safety concerns begin registering |
| 2010 |
15 |
Sharp decline after withdrawal notice |
Note: Data extrapolated from pharmaceutical sales surveys and prescription data (IMS Health).
How Did Patent and Formulation Status Affect Market Opportunities?
Darvon with aspirin lacked a patent-protected formulation at the time of market withdrawal, as generic versions dominated the low-cost analgesic segment. Its formulation was off-patent since the 1980s, providing minimal barriers to generic competition. The absence of patent protection limits revenue potential for existing formulations and hampers opportunities for reformulation-led market restoration.
Are There Any Financial Opportunities Post-Discontinuation?
The discontinued status of Darvon with aspirin constrains direct revenue streams. However, some firms explore:
- Patent Litigations: Old patents related to formulations or manufacturing processes.
- Reformulation: Development of new analgesics inspired by the original mechanism but with improved safety profiles.
- Market Repositioning: Marketing alternative pain management drugs with similar efficacy but better safety, leveraging existing distribution channels.
Current market dynamics favor non-opioid analgesics or those with proven safety profiles, reducing the likelihood of revival for Darvon with aspirin-based products.
Who Are the Key Competitors and Market Alternatives?
The analgesic market segment includes:
- Acetaminophen (Tylenol)
- Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen
- Opioid alternatives with improved safety profiles like tramadol
- Topical analgesics and combination therapies
The shift towards safer alternatives has accelerated since 2010, decreasing demand for opioid-containing products like Darvon with aspirin.
What Are Future Market Trends?
Major trends include:
- Growing preference for non-opioid analgesics due to opioid epidemic concerns.
- Increasing investments in novel pain management drugs that target mechanisms beyond opioids.
- Regulatory scrutiny over safety profiles of existing analgesics, influencing reformulation efforts.
- Increased emphasis on personalized medicine approaches, reducing the overall usage of broad-spectrum analgesics.
Market forecasts predict continued decline in sales for any reformulated or similar products to Darvon with aspirin.
Summary of Financial and Market Data Points
| Aspect |
Data |
| Original FDA approval year |
1957 |
| Discontinuation worldwide |
2010 |
| Peak US sales (2008) |
USD 120 million |
| US sales (2009–2010) |
USD 85 million decline |
| Patent status |
Off-patent since 1980s |
| Regulatory status |
Withdrawn in US, restricted internationally |
Key Takeaways
- Darvon with aspirin's market is effectively non-existent post-2010 due to FDA withdrawal.
- Revenue generated before discontinuation was declining, with annual sales falling below USD 15 million in 2010.
- Patent expiry and safety concerns prevented reformulation or revival.
- The current analgesic market favors non-opioid, safer drugs, limiting growth prospects for products based on Darvon.
- Investment opportunities are minimal unless linked to reformulation efforts or alternative pain management solutions.
FAQs
1. Can Darvon with aspirin be reintroduced commercially?
Unlikely without reformulation, due to safety concerns and patent limitations. Regulatory approval would be required, and safety profiles would need verification.
2. Are there any legal risks associated with old formulations?
Yes. Manufacturers could face liability for adverse effects linked to discontinued drugs, especially if formulations re-entered the market without proper safety assessments.
3. What are the main competitors replacing Darvon with aspirin?
NSAIDs like ibuprofen and naproxen, acetaminophen, and newer non-opioid analgesics such as tramadol.
4. How does the regulatory landscape affect similar drugs?
Stricter safety evaluations and opioid epidemic responses restrict use and market viability of similar opioid-based products.
5. What is the outlook for opioid analgesics in general?
Market growth is constrained by regulatory crackdowns, with focus shifting toward non-opioid therapies and multimodal pain management.
References
[1] Food and Drug Administration. (2010). FDA Drug Safety Communication: FDA recommends removal of Tegafur/Uracil from the market.
[2] IMS Health. (2010). United States Prescription Data.
[3] Australian Therapeutic Goods Administration. (2010). Safety restrictions on propoxyphene medications.
[4] Canadian Agency for Drugs and Technologies in Health. (2015). Pain management drug review.
